ArunA’s exosome entrance

Why ArunA decided to develop exosome therapeutics for stroke

Stem cell manufacturer ArunA Biomedical Inc. has announced a pivot into the exosome therapeutic space, as well as publication of the first data showing its neural stem cell-derived exosomes and other extracellular vesicles are effective in mouse models of stroke.

ArunA launched in 2003 to provide stem cells to the research community.

According to co-founder, CEO and CSO Steven Stice, the company’s move into therapeutics development was driven by opportunities it saw arising in

Read the full 729 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE